Division of CSL Ltd.
Latest From Seqirus
David Loew talked to Scrip about the next-generation meningococcal vaccine candidate MenQuadfi and a monoclonal antibody that may be the first RSV treatment for infants.
The agency is conducting a literature review of 8,000 articles to assess whether certain of eight licensed flu vaccines are more suitable for those 65 and older.
India's Glenmark gets US Complete Response Letter for Ryaltris but emphasizes the FDA hasn’t faulted the clinical data for the product, and that the action won’t impact recent alliances for the rhinitis asset.
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Gynecological, Urological
- Infectious & Viral Diseases
- Neurology, Nervous System
- CSL Biotherapies
- North America
- Parent & Subsidiaries
- CSL Ltd.
- Senior Management
- John Anderson, SVP & Gen. Mgr.
- Contact Info
Phone: (919) 577-5000
45 & 75 Sidney St.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.